drugset / Trial / NCT05356143
A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions
RandomizedCrossoverOpen-labelOther
Summary
This is an open-label, single-dose, randomized, three-period, two-treatment, threesequence, crossover, PK, partial replicate, and comparative bioavailability study. This study may be conducted in groups. The same protocol requirements and procedures will be followed for each group.
Timeline
- Start
- 2021-12-02
- Primary completion
- 2022-01-13
- Completion
- 2023-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rupatadine | Small molecule | 10 mg | Oral |
Indications
No indication recorded.